|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Severe COVID-19 patients exhibit an ILC2 NKG2D^(+) population in their impaired ILC compartment显示文摘Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is responsible for the current COVID-19 disease pandemic.In some patients,the symptoms are mild,and a fraction of SARS-CoV-2-infected individuals develop severe illness with a high fatality rate due to lung damage and acute respiratory distress syndrome.1 Innate lymphoid cells(ILCs)are a recently identified type of effector immune cells that rapidly sense environmental stimuli and participate in early immune responses by promptly secreting large amounts of cytokines.2 The ILC2 subpopulation was shown to mediate Type 2 responses and to recruit eosinophils during viral lung infections upon the release of alarmins(e.g.,IL-33)by damaged epithelial cells.3,4,5 ILC2s were also shown to participate in the termination of inflammatory responses and tissue repair by amphiregulin secretion.In addition,ILC2s are critical in the early phases of allergic lung inflammation,including that induced by the protease allergen papain.6 Based on the essential function of the papain-like protease PLpro in regulating SARS-CoV-27(Fig.1a)and the severe lung damage caused by this virus,we sought to investigate the potential involvement of ILC2s in immune responses to COVID-19. | Alejandra Gomez-Cadena Laurie Spehner Marie Kroemer Myriam Ben Khelil Kevin Bouiller Grégory Verdeil Sara Trabanelli Christophe Borg Romain Loyon Camilla Jandus | 2021 | Cellular & Molecular Immunology2021，18，2： | 2 |
| 2 | Metronomic cyclophosphamide: An alternative treatment for hepatic epithelioid hemangioendothelioma显示文摘 | Zaher Lakkis Stefano Kim Eric Delabrousse Marine Jary Thierry Nguyen Georges Mantion Bruno Heyd Catherine Lassabe Christophe Borg | 2013 | Journal of Hepatology2013，，6： | 1 |
| 3 | Lipophilic phenolic antioxidants: Correlation between antioxidant profile, partition coefficients and redox properties显示文摘 | Fernanda M.F. Roleira Christophe Siquet Elizabeta Orrù E. Manuela Garrido Jorge Garrido Nuno Milhazes Gianni Podda Fátima Paiva-Martins Salette Reis Rui A. Carvalho Elisiário J. Tavares da Silva Fernanda Borges | 2010 | Bioorganic & Medicinal Chemistry2010，，16： | 1 |
| 4 | FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer显示文摘AIM To evaluate the efficacy and safety of the modified FOLFIRI3-aflibercept as second-line therapy in patients with metastatic colorectal cancer.METHODS This is a retrospective multicenter cohort, evaluating the efficacy and safety of the association of aflibercept with FOLFIRI3(day 1: aflibercept 4 mg/kg, folinic acid 400 mg/m^2, irinotecan 90 mg/m^2, 5-fluorouracil infusion 2400 mg/m^2 per 46 h; day 3: irinotecan 90 mg/m^2) in patients with previously treated metastatic colorectal cancer. The primary endpoint was overall response rate(ORR). Secondary endpoints were disease control rate(DCR), progression-free survival(PFS), overall survival(OS), and safety.RESULTS Among 74 patients treated in four French centers, nine were excluded due to prior use of aflibercept(n = 3), more than one prior treatment line in irinotecanna?ve patients(n = 3), and inadequate liver function(n = 3). In the 'irinotecan-na?ve' patients(n = 30), ORR was 43.3% and DCR was 76.7%. Median PFS and OS were 11.3 mo(95%CI: 6.1-29.0) and 17.0 mo(95%CI: 13.0-17.3), respectively. The most common(> 5%) grade 3-4 adverse events were diarrhea(37.9%), neutropenia(14.3%), stomatitis and anemia(10.4%), and hypertension(6.7%). In the 'pre-exposed irinotecan' patients(n = 35), 20(57.1%) received ≥ 2 prior lines of treatment. ORR was 34.3% and DCR was 60.0%. Median PFS and OS were 5.7 mo(95%CI: 3.9-10.4) and 14.3 mo(95%CI: 12.8-19.5), respectively.CONCLUSION Minimally modified FOLFIRI has improvement dramatically the FOLFIRI3-aflibercept efficacy, whatever prior use of irinotecan. A prospective randomized trial is warranted to compare FOLFIRI-aflibercept to FOLFIRI3-aflibercept. | CANDice Carola Fran?ois Ghiringhelli Stefano Kim Thierry ANDré Juliette Barlet Le?la Bengrine-Lefevre Hélène Marijon Marie-Line Garcia-Larnicol Christophe Borg Linda Dainese Nils Steuer Hubert Richa Magdalena Benetkiewicz Annette K Larsen Aimery de Gramont Benoist Chibaudel | 2018 | World Journal of Clinical Oncology2018，9，5： | 1 |
| 5 | Comparison of local sine wave modeling with harmonic phase analysis for the assessment of myocardial strain显示文摘 | Christopher A. Miller Alex Borg David Clark Christopher D. Steadman Gerry P. McCann Patrick Clarysse Pierre Croisille Matthias Schmitt | 2013 | J. Magn. Reson. Imaging2013，，： | 1 |
| 6 | Impact of STAT3 Phosphorylation on the Clinical Effectiveness of Anti-EGFR–Based Therapy in Patients With Metastatic Colorectal Cancer显示文摘 | Erion Dobi Franck Monnien Stefano Kim Arben Ivanaj Thiery N’Guyen Martin Demarchi Olivier Adotevi Antoine Thierry-Vuillemin Marie Jary Bernadette Kantelip Xavier Pivot Yann Godet Severine Valmary Degano Christophe Borg | 2012 | Clinical Colorectal Cancer2012，，： | 1 |
| 7 | Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study显示文摘 | Jaafar Bennouna Christophe Borg Jean-Pierre Delord Faress Husseini Véronique Trillet-Lenoir Roger Faroux Eric Fran?ois Marc Ychou Fran?ois Goldwasser Olivier Bouché Helene Senellart Sandrine Kraemer Jean-Yves Douillard | 2012 | Clinical Colorectal Cancer2012，，1： | 1 |
| 8 | FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study显示文摘BACKGROUND FOLFIRINOX regimen is the first-line reference chemotherapy(L1)in advanced pancreatic ductal adenocarcinoma(aPDAC).FOLFOXIRI,a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil,has demonstrated efficacy and feasibility in colorectal cancer.AIM To investigate the potential clinical value of FOLFOXIRI in patients with aPDAC in routine clinical practice.METHODS Analyses were derived from all consecutive aPDAC patients treated in L1 between January 2011 and December 2017 in two French institutions,with either FOLFOXIRI(n=165)or FOLFIRINOX(n=124)regimens.FOLFOXIRI consisted of irinotecan(165 mg/m2),oxaliplatin(85 mg/m2),leucovorin(200 mg/m2)and 5-fluorouracil(3200 mg/m2 as a 48-h continuous infusion)every 2 wk.Ninety-six pairs of patients were selected through propensity score matching,and clinical outcomes of the two treatment regimens were compared.RESULTS Median overall survival was 11.1 mo in the FOLFOXIRI and 11.6 mo in the FOLFIRINOX cohorts,respectively.After propensity score matching,survival rates remained similar between the two regimens in terms of overall survival(hazard ratio=1.22;P=0.219)and progression-free survival(hazard ratio=1.27;P=0.120).The objective response rate was 37.1%in the FOLFOXIRI group vs 47.8%in the FOLFIRINOX group(P=0.187).Grade 3/4 toxicities occurred in 28.7%of patients in the FOLFOXIRI cohort vs 19.5%in the FOLFIRINOX cohort(P=0.079).FOLFOXIRI was associated with a higher incidence of grade 3/4 digestive adverse events.Hematopoietic growth factors were used after each chemotherapy cycle and the low hematological toxicity rates were below 5%with both regimens.CONCLUSION FOLFOXIRI is feasible in L1 in patients with aPDAC but does not confer any therapeutic benefit as compared with FOLFIRINOX.The low hematological toxicity rates strengthened the relevance of primary prophylaxis with hematopoietic growth factors. | Angélique Vienot Hortense Chevalier Clément Bolognini Elisabeta Gherga Elodie Klajer Aurélia Meurisse Marine Jary Stefano Kim Christelle d’Engremont Thierry Nguyen Fabien Calcagno Hamadi Almotlak Francine Fein Meher Nasri Syrine Abdeljaoued Anthony Turpin Christophe Borg Dewi Vernerey | 2020 | World Journal of Gastrointestinal Oncology2020，12，3： | 0 |
| 9 | CD8^(+)CD226^(high)T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery显示文摘CD226 has been reported to participate in the rescue of CD8^(+)T cell dysfunction.In this study,we aimed to assess the prognostic value of CD226 in tumor-infiltrating lymphocytes(TILs)derived from colorectal cancer(CRC)liver metastases treated with chemotherapy and radical surgery.TILs from 43 metastases were isolated and analyzed ex vivo usingflow cytometry.CD155 and CD3 levels in the tumor microenvironment were assessed by immunohistochemistry.Exploration and validation of biological processes highlighted in this study were performed by bioinformatics analysis of bulk RNA-seq results for 28 CRC liver metastases pretreated with chemotherapy as well as public gene expression datasets.CD226 expression contributes to the definition of the immune context in CRC liver metastases and primary tumors.CD226 on CD8^(+)T cells was not specifically coexpressed with other immune checkpoints,such as PD1,TIGIT,and TIM3,in liver metastases.Multivariate Cox regression analysis revealed CD226 expression on CD8^(+)T cells to be an independent prognostic factor(p=0.003),along with CD3 density at invasion margins(p=0.003)and TIGIT expression on CD4^(+)T cells(p=0.019).CD155 was not associated with the prognostic value of CD226.Gene expression analysis in a validation dataset confirmed the prognostic value of CD226 in CRC liver metastases but not in primary tumors.Downregulation of CD226 on CD8^(+)TILs in the liver microenvironment was restored by IL15 treatment.Overall,CD226 expression on liver metastasis-infiltrating CD8^(+)T cells selectively contributes to immune surveillance of CRC liver metastases and has prognostic value for patients undergoing radical surgery. | Julien Viot Syrine Abdeljaoued Angélique Vienot Evan Seffar Laurie Spehner Adeline Bouard Kamal Asgarov Jean-RenéPallandre Elodie Renaude Elodie Klajer ChloéMolimard Franck Monnien Frederic Bibeau Celia Turco Bruno Heyd Paul Peixoto Eric Hervouet Romain Loyon Alexandre Doussot Christophe Borg Marie Kroemer | 2023 | Cellular & Molecular Immunology2023，20，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员